Allakos Inc (ALLK) is a clinical-stage biotechnology company focused on developing therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company's lead product candidate, AK002, is an investigational monoclonal antibody that targets eosinophils and mast cells, two types of immune cells that play a key role in allergic and inflammatory diseases.
AK002 is being evaluated in multiple clinical trials for the treatment of various conditions, including eosinophilic gastritis and duodenitis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. In addition to AK002, Allakos is also developing other product candidates targeting different immune cells and pathways involved in various allergic and inflammatory diseases. The company is headquartered in Redwood City, California and was founded in 2012.
Allakos Inc (ALLK) is a clinical-stage biotechnology company focused on developing therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company's lead product candidate, AK002, is an investigational monoclonal antibody that targets eosinophils and mast cells, two types of immune cells that play a key role in allergic and inflammatory diseases.